Malaysia Oral Anti-Diabetic Drug Market - Growth, Trends, COVID-19 Impact, and Forecasts (2024 - 2029)

The Malaysia Oral Anti-Diabetic Drug Market is Segmented Into Drugs (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-d2 Receptor Agonists, Sodium-glucose Cotransport-2 (SGLT-2) Inhibitor, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Sulfonylureas, And Meglitinides), And Geography. The Report Offers the Value (in USD) and Volume (in Units) for the Above Segments.

Malaysia Oral Anti-Diabetic Drug Market - Growth, Trends, COVID-19 Impact, and Forecasts (2024 - 2029)

Malaysia Oral Anti-Diabetic Drug Market Size

Malaysia Oral Anti-Diabetic Drug Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Historical Data Period 2019 - 2022
Market Size (2024) USD 274 Million
Market Size (2028) USD 333 Million
CAGR (2024 - 2029) 3.00 %

Major Players

Malaysia Oral Anti-Diabetic Drug Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Malaysia Oral Anti-Diabetic Drug Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Malaysia Oral Anti-Diabetic Drug Market Analysis

The Malaysia Oral Anti-Diabetic Drug Market size is estimated at USD 274 million in 2024, and is expected to reach USD 333 million by 2028, growing at a CAGR of greater than 3% during the forecast period (2024-2028).

According to the Health Ministry, one in five Malaysians, or around 3.9 million adults and older, have diabetes. There are more young people with diabetes. The prevalence of diabetes is rising among younger people, with the number of diabetics in this age group more than doubling in the past 15 years. 

Diabetes complications, such as heart disease, stroke, blindness, chronic kidney disease, and lower limb amputation, are becoming more prevalent due to the expanding diabetes population. Most coronavirus mortality in Malaysia is caused by underlying comorbidities, with diabetes and hypertension at the top.

Diabetes among young people is on the rise. With the number of patients between the ages of 18 and 40 having doubled over the previous 15 years, younger individuals are developing diabetes. The burden of diabetes and its consequences, such as heart disease, stroke, blindness, chronic kidney disease, and lower limb amputation, is increasing as the number of people with diabetes grows.

Malaysia Oral Anti-Diabetic Drug Industry Overview

The Malaysia oral anti-diabetes drug market is consolidated, with a few major manufacturers like Eli Lilly, AstraZeneca, Sanofi, and Janssen Pharmaceuticals having a global market presence. In contrast, the remaining manufacturers are confined to the other local or regional markets. Companies are focusing on innovations in diabetes drugs.

Malaysia Oral Anti-Diabetic Drug Market Leaders

  1. Astrazeneca

  2. Astellas

  3. Janssen

  4. Eli Lilly

  5. Sanofi

  6. *Disclaimer: Major Players sorted in no particular order
Malaysia Oral Anti-Diabetic Drug Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Malaysia Oral Anti-Diabetic Drug Market News

  • June 2023: The FDA has approved the drugs Jardiance and Synjardy to be taken by children ages 10 and older who have type 2 diabetes.
  • May 2022: Tirzepatide (Mounjaro) was approved for treating Type 2 diabetes in adults. Tirzepatide's FDA approval marks the first in a new class of diabetes medications: a dual GIP/GLP-1 receptor agonist.

Malaysia Oral Anti-Diabetic Drug Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
  • 4.3 Market Restraints
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products and Services
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION

  • 5.1 Oral Anti-diabetic drugs
    • 5.1.1 Biguanides
    • 5.1.1.1 Metformin
    • 5.1.2 Alpha-Glucosidase Inhibitors
    • 5.1.2.1 Alpha-Glucosidase Inhibitors
    • 5.1.3 Dopamine D2 receptor agonist
    • 5.1.3.1 Bromocriptin
    • 5.1.4 SGLT-2 inhibitors
    • 5.1.4.1 Invokana (Canagliflozin)
    • 5.1.4.2 Jardiance (Empagliflozin)
    • 5.1.4.3 Farxiga/Forxiga (Dapagliflozin)
    • 5.1.4.4 Suglat (Ipragliflozin)
    • 5.1.5 DPP-4 inhibitors
    • 5.1.5.1 Onglyza (Saxagliptin)
    • 5.1.5.2 Tradjenta (Linagliptin)
    • 5.1.5.3 Vipidia/Nesina(Alogliptin)
    • 5.1.5.4 Galvus (Vildagliptin)
    • 5.1.6 Sulfonylureas
    • 5.1.6.1 Sulfonylureas
    • 5.1.7 Meglitinides
    • 5.1.7.1 Meglitinides

6. MARKET INDICATORS

  • 6.1 Type-1 Diabetic Population
  • 6.2 Type-2 Diabetic Population

7. COMPETITIVE LANDSCAPE

  • 7.1 COMPANY PROFILES
    • 7.1.1 Takeda
    • 7.1.2 Novo Nordisk
    • 7.1.3 Pfizer
    • 7.1.4 Eli Lilly
    • 7.1.5 Janssen Pharmaceuticals
    • 7.1.6 Astellas
    • 7.1.7 Boehringer Ingelheim
    • 7.1.8 Merck And Co.
    • 7.1.9 AstraZeneca
    • 7.1.10 Bristol Myers Squibb
    • 7.1.11 Novartis
    • 7.1.12 Sanofi
  • *List Not Exhaustive

8. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Malaysia Oral Anti-Diabetic Drug Industry Segmentation

Orally administered antihyperglycemic drugs reduce blood glucose levels. They are often used in Type 2 diabetes care. The Malaysia Oral Anti-Diabetic Drug Market is segmented into drugs. The report offers the value (in USD) and volume (in Units) for the above segments.

Oral Anti-diabetic drugs Biguanides Metformin
Oral Anti-diabetic drugs Alpha-Glucosidase Inhibitors Alpha-Glucosidase Inhibitors
Oral Anti-diabetic drugs Dopamine D2 receptor agonist Bromocriptin
Oral Anti-diabetic drugs SGLT-2 inhibitors Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Suglat (Ipragliflozin)
Oral Anti-diabetic drugs DPP-4 inhibitors Onglyza (Saxagliptin)
Tradjenta (Linagliptin)
Vipidia/Nesina(Alogliptin)
Galvus (Vildagliptin)
Oral Anti-diabetic drugs Sulfonylureas Sulfonylureas
Oral Anti-diabetic drugs Meglitinides Meglitinides
Need A Different Region or Segment?
Customize Now

Malaysia Oral Anti-Diabetic Drug Market Research Faqs

How big is the Malaysia Oral Anti-Diabetic Drug Market?

The Malaysia Oral Anti-Diabetic Drug Market size is expected to reach USD 274 million in 2024 and grow at a CAGR of greater than 3% to reach USD 333 million by 2028.

What is the current Malaysia Oral Anti-Diabetic Drug Market size?

In 2024, the Malaysia Oral Anti-Diabetic Drug Market size is expected to reach USD 274 million.

Who are the key players in Malaysia Oral Anti-Diabetic Drug Market?

Astrazeneca, Astellas, Janssen, Eli Lilly and Sanofi are the major companies operating in the Malaysia Oral Anti-Diabetic Drug Market.

What years does this Malaysia Oral Anti-Diabetic Drug Market cover, and what was the market size in 2023?

In 2023, the Malaysia Oral Anti-Diabetic Drug Market size was estimated at USD 265.78 million. The report covers the Malaysia Oral Anti-Diabetic Drug Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Malaysia Oral Anti-Diabetic Drug Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.

Malaysia Oral Anti-Diabetic Drug Industry Report

Statistics for the 2024 Malaysia Oral Anti-Diabetic Drug market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Malaysia Oral Anti-Diabetic Drug analysis includes a market forecast outlook to for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.